Development and performance evaluation of a low-cost in-house rRT-1

PCR assay in Ecuador for the detection of SARS-CoV-2. 2

- Marco A. Salinas^a, Diana F. Aguirre^a, David I. De la Torre^a, Jorge Pérez-Galarza^{a,b}, Ronny J. 3
- Pibaque^a, Paul A. Beltran^a, Tatiana J. Veloz^a, Lucy Y. Baldeón^{a,b}. 4
- 5 ^a Research Institute of Biomedicine, Central University of Ecuador, Quito 170201, Ecuador
- 6 ^b Faculty of Medicine, Central University of Ecuador, Ouito 170403, Ecuador.
- 7 Corresponding author.
- 8 Marco A. Salinas: masalinas@uce.edu.ec

9 ABSTRACT

Antecedents: Ecuador has had the greatest fatality rate from Coronavirus (COVID-19) in South 10

- America during the SARS-CoV-2 pandemic. To control the pandemic, it is necessary to test as much 11
- population as possible to prevent the spread of the SARS-CoV-2 infection. For the Ecuadorian 12
- population, accessing a PCR test is challenging, since commercial screening kits tend to be 13
- expensive. Objective: the objective of this study was to develop an in-house duplex rRT-PCR 14 15
- protocol for the detection of SARS-CoV-2 that contributes to the screening while keeping quality and low testing costs. Results: An in-house duplex rRT-PCR protocol based on the viral envelope 16
- (E) gene target of SARS-CoV-2 and a human ribonuclease P gene (RP) as an internal control is 17
- 18 reported. The protocol was optimized to obtain primers E with an efficiency of up to 94.45% and
- 19 detection of 100% of SARS-CoV-2 up to 15 copies per uL. The clinical performance was determined
- by a sensibility of 93.8% and specificity of 98.3%. Conclusion: we developed, standardized, and 20
- 21 validated a low-cost, sensitive in-house duplex rRT-PCR assay that may be utilized in low-income
- 22 countries.
- 23 Keywords: COVID-19, coronavirus, E gene, in-house, rRT-PCR.

1. Introduction 24

- 25 On March 11, 2020, the World Health Organization (WHO) designated coronavirus disease 2019
- (COVID-19) outbreak a pandemic and an international public health emergency [1]. COVID-19 26
- disease is caused by a novel coronavirus, which is highly infectious and can induce severe acute 27

respiratory syndrome (SARS-CoV2). Until June 2021, the number of cases reported is more than 180 28

- 29 million infections and more than 3 million deaths around the world [2]. The World Health 30 Organization (WHO) recorded 360 thousand confirmed illnesses and over 18 thousand fatalities in
- Ecuador. 31
- Ecuador has the highest case fatality rate in the area (4.9 percent) [3]. Furthermore, the country's 32
- death rate increased by 24% in the first trimester of 2021 (mortality comparison between December 33
- 34 2019 and March 2020 vs. December 2020 and March 2021) [4].
- 35 The existence of asymptomatic persons confuses the precise number of infected patients, which is a
- 36
- possible danger that stays latent for the disease's spread. As a result, the rate of SARS-CoV-2 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. infection may be greater than previously thought. [5]. This scenario emphasizes population-wide 37

- 38 testing and, as a result, the availability of specialized tests for early viral identification and the
- implementation of pandemic control epidemiological methods. [6]. Ecuador is one of the countries in 39
- 40 South America with the lowest number of tests per capita (0.2 per 1000 persons each day) [7].

The gold standard for SARS-CoV-2 detection is a viral nucleic acid detection technique based on 41 real-time reverse transcriptase-PCR (rRT-PCR). Commercial kits based on rRT-PCR have been in 42

43 great demand across the world due to the technique's excellent sensitivity and specificity in

- 44 accurately detecting the virus [8]. The US Food and Drug Administration (FDA) has approved
- 45 various rRT-PCR assays targeting viral genes such as nucleocapsid (N), envelope (E), and RNA-
- 46 dependent RNA polymerase (RNA-dependent RNA polymerase) (RdRp) [9]. However, numerous
- tests have shown that the E gene is somewhat more sensitive than other genetic targets, and the Pan 47
- 48 American Health Organization (PAHO) has advised that the E gene be utilized exclusively for viral
- 49 population screening in the Americas during this emergency [10].

50 Because of the COVID-19 pandemic, there has been an increase in the global demand for rRT-PCR 51 commercial kits for detecting SARS-CoV-2. The scarcity of kits is worse in low-income countries 52 like Ecuador, where the cost of these kits makes them inaccessible to the government and the general population. Many laboratories have created in-house assays with excellent sensitivity and specificity 53 54 to tackle this challenge by emphasizing test cost reduction. In addition, to minimize the transmission

55 of the virus by asymptomatic persons, the majority of the population must be screened. Our goal was to develop an in-house duplex rRT-PCR test that would identify SARS-CoV-2 in human respiratory 56

57 samples using the E gene.

2. Materials and Methods 58

59 **2.1.** Primers and probes

For the duplex standardization experiment, two sets of primer pairs and probes for the viral E gene 60 61 and human ribonuclease P (RP) (internal control) were employed. A multiplex assay was also attempted using primers targeting RdRp gene. E and RdRp primers/probes were obtained from the 62 study published by Charité-Universitatsmedizin Berlin Institute of Virology [11]. RP primer/probe 63 was obtained from the United States of America Centre for Disease Control and Prevention (CDC) 64 [12]. The probes were labelled with FAM, ROX, and VIC for E, RdRp, and RP, respectively (see 65 Table 1). All primers and probes were purchased from Eurofins Scientific (Kentucky, USA). 66

- 67
- 68 69
- 70
- 71
- 72
- 73
- 74
- 75 76
- 77
- 78
- 79
- 80

Target gene	Sequence (5'-3')	Reference
Gen-E Forward	ACA GGT ACG TTA ATA GTT AAT AGC GT	_
Gen-E Reverse	ATA TTG CAG CAG TAC GCA CAC A	
Gen-E Probe	FAM-ACA CTA GCC ATC CTT ACT GCG CTT CG-	
	BHQ1	Corman, et al.
RdRp-Forward	GTG ARA TGG TCA TGT GTG GCG G	(2020)
RdRp-Reverse	CAR ATG TT A AAA ACA CTA TTA GCA TA	
Gen-RdRp	ROX-CAG GTG GAA CCT CAT CAG GAG ATG C-	
Probe	BHQ1	
RP-Forward	AGA TTT GGA CCT GCG AGC G	
RP-Reverse	GAG CGG CTG TCT CCA CAA GT	Lu, et al. (2020)
Gen-RP Probe	VIC-TTC TGA CCT GAA GGC TCT GCG CG-BHQ1	

82 Abbreviations: RdRp= RNA-dependent RNA polymerase, Rp= human ribonuclease P

83 2.2. rRT-PCR reaction optimization

81

To develop the assay, a SARS-CoV-2 RNA source (RNA standardization solution) with a known 84

85 concentration (3.81 x 105 viral copies per uL) was used. To optimize the final reaction setup,

86 simplex assays were done. Three sets of primers/probes were used in different concentrations. The

thermocycler program was set up using temperature gradient at 56, 58, and 60 °C. Amplification 87

88 products were observed by electrophoresis (2% agarose gel) to verify the specificity of the primers.

89 With 5 and 3.3 uL of RNA standardization solution, respectively, a final volume of 20 and 10 uL

90 was tested. The master mix was prepared with the GoTaq Probe 1-step RT-qPCR System reagent (Promega, USA). The QuantStudio 5 Real-Time PCR equipment (Applied Biosystems, USA) and 91

92 BioRad CFX96 (BioRad Laboratories, USA) were used to perform the experiments.

93 2.3. In-house duplex and multiplex rRT-PCR develop

94 5 uL of 1X GoTaq Probe qPCR Master Mix, 0.2 uL of 50X GoScript RT Mix 1-Step RT-qPCR, 30 nM CRX reference dye (only for QuantStudio 5), 400/200 nM primers/probe E gene, 200/100 nM 95 primers/probe RP gene, and 3.3 uL of RNA standardization solution were used to make an in-house 96 97 duplex assay. Thermal cycling conditions were 45 °C for 15 min, 95 °C for 2 min, and 40 cycles of 98 95 °C for 15 secs and 60 °C for 30 secs. For the multiplex assay, 300/150 nM primers/probe RdRp 99 were added to the duplex setup and RNA standardization solution was decreased to 2.5 uL.

100 2.4. Limit of detection (LoD) of duplex rRT-PCR

101 To assess the efficiency of E primers, successive dilutions of the RNA standardization solution were produced in the range of 512 to 16 copies per uL. Serial dilutions were reduced from 64 to 1 copy 102 103 per uL for the LoD of the duplex test. Three distinct operators carried out each test independently, 104 and the reactions were produced in triplicate.

2.5. Clinical evaluation and ethical approval 105

- 106 The in-house assay was created and tested at the Research Institute in Biomedicine of Central
- 107 University of Ecuador (INBIOMED-UCE). The researchers utilized stored RNA from
- nasopharyngeal swab samples from COVID-19 suspects who visited INBIOMED in February 2021. 108
- 109 The Ministry of Public Health of Ecuador ethically approved the in-house SARS-CoV-2 assay.

2.6. Agreement and Performance 110

The sample was calculated to achieve a 95 percent level of significance and an 8 percent inference 111

112 error. Taking into consideration a 25% probability of positive. As a result, the sample's computed N

was 112, which was raised by 10% to account for probable losses, yielding 124 samples. There were 113

- 64 COVID-19 positive samples and 60 COVID-19 negative samples in the study. To evaluate the 114
- 115 agreement/performance, we compared the in-house duplex rRT-PCR results against the commercial
- LightMix SarbecoV E-gene plus EAV control kit and LightMix Modular SARS-CoV-2 (COVID-19) 116
- 117 RdRp (TibMolBiol. Germany). For the LightMix E/RdRp kit, the samples were diagnosed as
- 118 positive for SARS-CoV-2 when at least one viral gene had a valid CT value [10].

119 2.7. Viral RNA Extraction and in-house duplex rRT-PCR

120 The Nucleic Acid Extraction kit (Magnetic bead technique) (Zybio, China) was used to extract RNA

121 from 200 uL of the sample, with an elution volume of 50 uL, according to the manufacturer's

122 instructions. The RNA was kept at -80 °C until it was needed. An in-house duplex technique was

123 used to accomplish the rRT-PCR. The reactions for the LightMix E/RdRp kit were carried out

124 according to the manufacturer's instructions. Bio-Rad CFX96 was used to run the samples.

125 2.8. Statistical analysis

126 We calculate the positive percent agreement (sensitivity), negative percent agreement (specificity),

positive and negative predictive values, likelihood ratio, and Cohen's Kappa to assess the duplex 127

128 rRT-PCR test in clinical samples. SPSS software version 23 was used for the analysis (IBM).

3. Results 129

130 3.1. rRT-PCR optimization

Simplex rRT-PCR experiments were prepared to find the optimal primers and probes concentration. 131

132 The amplicons of these assays were located at the expected positions for the fragment lengths which

133 were 113 bp, 100 bp, and 50 bp for the E, RdRp, and RP respectively. For the RP set, a low variation

in the Ct was observed when changing RP primer concentrations from 600 nM to 200 nM (with half 134

of the concentration of its probe). For this reason, 200/100 nM primers/probe concentration was 135

136 chosen for all following assays. In the case of E and RdRp sets, 400/200 nM and 300/150 nM,

- respectively, was chosen for the remaining experiments because this primers/probe concentration 137
- 138 had one of the lowest Ct (E=18.40, RdRp=25.65). As for the annealing temperature, the lowest Ct
- 139 for the E pair of primers was prioritized. The temperature was 60 °C (Data not shown).

3.2. In-house duplex and multiplex SARS-CoV-2 assays 140

Upon optimization of reaction conditions on the simplex set-up we performed a duplex protocol, 141 142 which had more consistent results than the multiplex protocol. When the Ct value of a target changed 143 in more than one of the E and RP sets of primers/probes (Duplex) and E, RdRp, and RP (Multiplex) primers/probes, the reactions were declared invalid. E target had Ct values consistent across all 144 145 assays (Ct 21.77 simplex, 21.83 duplex, 22.13 multiplex). RP readout, which was used to measure genetic material quality, exhibited similar Ct variation to the E gene, with no more than 0.5. (23.69 146 147 duplex, 24.19 multiplex). RdRp profiles were found to be less reproducible than the other two 148 targets, although their Ct values were within a respectable margin of error between replicates (no 149 more than 0.5) (see Figure 1). At low quantities of viral RNA (15 viral copies/reaction), the RdRp

150 target showed weak or no amplification curves in further multiplex tests. With a final volume of 10


uL, all reactions were carried out. Reducing the reaction volume from 20 uL to 10 uL, and therefore 151

the volume of RNA standardization solution from 5 uL to 3.3 uL, yielded the same findings without 152

153 interfering with the amplification of E and RP targets. QuantStudio 5 and BioRad CFX96 were both

154 compatible with the duplex test.





156

157 Figure 1. Amplification plots for duplex and multiplex protocols. Plots were obtained from a QuantStudio 5 Real-Time 158 PCR system with detections of the target genes (E, RP, and RdRp).


3.3. LoD of the in-house duplex assay 159

160 Serial dilutions of the RNA standardization solution (64, 32, 15, 10, 5, 2, 1 copies/uL) were prepared 161 for LoD evaluation. 15 copies/uL (49.5 copies/reaction) with a mean Ct value of 35.99 (CI95 percent 35.33 - 36.66) was the lowest concentration at which all nine replicates (100%) showed 162 163 amplification curves. (see Table 2). Moreover, the primer efficiency was 94.45%, with an R2 of 98.1

percent. (see Figure 2). 164

165	Table 2. Confirmatory LoD Testing Results.					
	Target level	N° Valid tested	SARS-CoV-2 E Gene Positive			
	(copies/uL)	replicates	n*	Mean Ct	Detection rate	
	64	9	9	34.05	100%	
	32	9	9	35.25	100%	
	15	9	9	35.99	100%	
	10	9	5	35.74	55.56%	
	5	9	6	37.23	66.67%	
	2	9	4	35.60	44.44%	
	1	9	2	35.89	22.22%	

166 * This column contains only valid replicates



168 Figure 2. Standard curve plot of E gene from 2-fold serial dilutions of RNA standardization solution (512, 256, 128, 64, 169 32, 16 copies/uL). Primers' efficiency = 94.45 %, slope -3.619 and R2 = 0.981.

3.4. Clinical Evaluation 170

167

171 For clinical comparison, we used the commercial LightMix SarbecoV E-gene + EAV control kit, 172 which identified 64 positives and 60 negatives in nasopharyngeal samples. Sixty-four out of sixty-173 four samples were found to be positive using an in-house duplex method. The in-house duplex procedure found 60 out of 64 samples to be positive (see Table S1 in the Supplementary Material). 174 Four samples were missed by the duplex test, resulting in 93.8 % sensitivity, 98.3 % specificity, a 175 Likelihood ratio of 56.25, and a Cohen's K of 0.92 (see Table 3). 176

177 Table 3. Clinical performance indicators of concordance of E target with in-house duplex rRT-PCR vs. LightMix 178 E/RdRp kit.

	Sensitivity (%)	Specificity (%)	PPV	NPV	LR	Карра
	(CI95%)	(CI95%)				
In-house duplex	93.8	98.3	98.4	93.7	56.25	0.92
rRT-PCR	(84.8-98.3)	(91.1-100)	(91.2-100)	(84.5-98.2)		

179 Abbreviations: CI95% = Confidence Interval, PPV = Positive Predictive Value, NPV = Negative Predictive Value, LR =

180 Likelihood Ratio, Kappa = Cohen's Kappa Index

4. Discussion 181

182 Ecuador is one of the South American countries worst hit by the COVID-19 pandemic. Molecular

diagnostics using rRT-PCR is the best approach to detect SARS-CoV-2 virus to restrict its spread 183

until we achieve herd immunity in the nation. An improved and reproducible rRT-PCR methodology 184

185 for the diagnosis of COVID-19 using a viral gene (E) and a human gene (Rp) in a simple reaction

was designed in this work, using primers built according to recognized international guidelines 186

[11,12]. As a result, 113-bp bands for the E gene and 55-bp bands for the Rp gene were produced 187

188 without nonspecific products such as dimers or overlapping sequences that might cause false

189 positives during the amplification process [13].

190 The sets of primers/probes for the detection of the E and RdRp genes employed to standardize the technique have a reasonably low nonselective mutation rate and have been reported in similar 191 researches [14,15]. Following the guidelines of the US Centers for Disease Control and Prevention 192 193 (CDC), the Rp gene was utilized as an internal control of RNA extraction [16]. The E gene showed 194 little variability in duplex and multiplex reactions, according to the amplification graph (Figure 1). In 195 contrast, using the RdRp gene, repeatability and effectiveness were dramatically reduced at low viral 196 doses. In accordance with findings from numerous studies, which suggest that the RdRp gene set of primers/probe is less sensitive than the E gene [17,18]. For this reason, the E gene duplex 197 combination was chosen. In contrast to Corman et al., who reported a LoD of 3.9 copies/reaction 198 199 (95% CI: 2.8–9.8) [11]., we detected 49.5 copies/reaction for the E gene with a probability of 100 % 200 detection (Table 2). The type of reagents and equipment used during the test might explain the 201 variation in LoD [19-21].

202 The clinical assessment of the kit revealed that it has a diagnostic sensitivity of 93.8 % and a specificity of 98.3 %, implying a 6.2 % false negative rate and a 1.7 % false positive rate. In the 203 assessed population, the degree of agreement of the findings between in-house rRT-PCR and the 204 205 commercial LightMix SarbecoV gene E kit is strong (Kappa index = 0.92). Furthermore, our kit has 206 a positive predictive value of 98.4%, indicating that in a positive test, this percentage of persons actually has the condition. The 93.7 % negative predictive value indicates that 93.7 percent of those 207 208 who get a negative screening test do not have the disease. Meanwhile, the odds of exposure among 209 case-patients are 56 times greater than the odds of exposure among controls.

210 The limitation of the in-house duplex test is that it can only identify one viral gene (E) and one

internal control gene (Rp). However, the kappa index (0.92) shows that our protocol is comparable to 211

commercial kits (LightMix E / RdRp) that screen two or more viral genes. Furthermore, because the 212

213 E gene is unique to all Sarbecoviruses and because SARS-CoV-2 is the only member of the family

214 now circulating in humans, the WHO has recommended that the E gene be prioritized as a target. In

this approach, a single viral genetic target suffices for case confirmation in the lab. 215

5. Conclusions 216

In conclusion, we designed, standardized, and validated an in-house duplex rRT-PCR assay that can 217

detect SARS-CoV-2 virus presence up to 15 copies/uL. This approach can assist our country enhance 218

219 its capacity to screen both symptomatic and asymptomatic carriers by making SARS-CoV-2 rRT-

220 PCR more accessible.

6. Ethical Statement 221

- 222 This study was approved by Health Intelligence Directorate of the Ministry of Public Health of
- 223 Ecuador through resolution No MSP-CGDES-2020-0259-O.

7. Data Availability 224

225 The [TABULAR DATASET] data used to support the findings of this study have been deposited in 226 the [4TU.RESEARCHDATA] repository (https://figshare.com/s/1dccb42f2189fbd42a65).

8. Conflict of interest 227

228 The authors declare that there is no conflict of interest regarding the publication of this paper.

9. Funding 229

230 This work was supported by the Académie De Recherche Et D'Enseignement Supérieur – Central 231 University of Ecuador (ARES-UCE) and Empresa Pública de Bienes y Servicios - Central University of Ecuador (EP-UCE).

232

10. Acknowledgment 233

234 We are extremely grateful to Central University of Ecuador, for his support in managing the needed 235 funds for the development of this in-house duplex rRT-PCR protocol that would have a great

236 positive impact in our society.

237 **11. Supplementary Materials**

- 238 The Table S1 used to support the findings of this study has been deposited in the
- [4TU.RESEARCHDATA] repository (https://figshare.com/s/1dccb42f2189fbd42a65). 239

12. References 240

- 241 [1] World Health Organization (WHO), "WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020," 2020. https://www.who.int/director-242
- 243 general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-oncovid-19---11-march-2020. 244
- 245 [2] World Health Organization (WHO), "COVID-19 weekly epidemiological update, 29 June
- 246 2021," 2021. https://www.who.int/publications/m/item/weekly-epidemiological-update-on-247 covid-19---29-june-2021.
- World Health Organization (WHO), "Geo-Hub COVID-19 Information System for the 248 [3] Region of the Americas," 2021, [Online]. Available: https://paho-covid19-response-249 who.hub.arcgis.com/pages/paho-south-america-covid-19-response. 250
- Registro Civil, "Cifras de Defunciones," 2021. https://www.registrocivil.gob.ec/cifras/ 251 [4] 252 (accessed Jun. 05, 2021).
- 253 [5] V. Caturano et al., "Estimating asymptomatic SARS-CoV-2 infections in a geographic area of 254 low disease incidence," BMC Infect. Dis., vol. 21, no. 1, pp. 2-5, 2021, doi: 10.1186/s12879-255 021-06054-2.
- S. Chadsuthi and C. Modchang, "Modelling the effectiveness of intervention strategies to 256 [6] control COVID-19 outbreaks and estimating healthcare demand in Germany," Public Heal. 257
- 258 *Pract.*, vol. 2, 2021, doi: https://doi.org/10.1016/j.puhip.2021.100121.
- J. Hasell et al., "A cross-country database of COVID-19 testing," Sci. Data, vol. 7, no. 1, pp. 259 [7] 260 1-7, 2020, doi: 10.1038/s41597-020-00688-8.

261	[8]	M. Shen et al., "Recent advances and perspectives of nucleic acid detection for coronavirus,"
262		J. Pharm. Anal., vol. 10, no. 2, pp. 97-101, 2020, doi: 10.1016/j.jpha.2020.02.010.
263	[9]	S. L. Mitchell et al., "Understanding, verifying, and implementing emergency use
264		authorization molecular diagnostics for the detection of sars-cov-2 RNA," J. Clin. Microbiol.,
265		vol. 58, no. 8, pp. 1-8, 2020, doi: 10.1128/JCM.00796-20.
266	[10]	World Health Organization (WHO), "Laboratory Guidelines for the Detection and Diagnosis
267		of COVID-19 Virus Infection," Paho, no. Julio, pp. 1–7, 2020, [Online]. Available:
268		https://iris.paho.org/bitstream/handle/10665.2/52458/PAHOIMSPHECOVID-
269		19200038_eng.pdf?sequence=1&isAllowed=y.
270	[11]	V. M. Corman et al., "Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-
271		PCR," Eurosurveillance, vol. 25, no. 3, 2020, doi: 10.2807/1560-7917.ES.2020.25.3.2000045.
272	[12]	X. Lu et al., "US CDC real-time reverse transcription PCR panel for detection of severe acute
273		respiratory syndrome Coronavirus 2," Emerg. Infect. Dis., vol. 26, no. 8, pp. 1654–1665,
274		2020, doi: 10.3201/eid2608.201246.
275	[13]	M. Park, J. Won, B. Y. Choi, and C. J. Lee, "Optimization of primer sets and detection
276		protocols for SARS-CoV-2 of coronavirus disease 2019 (COVID-19) using PCR and real-time
277		PCR," Exp. Mol. Med., vol. 52, no. 6, pp. 963–977, Jun. 2020, doi: 10.1038/s12276-020-0452-
278		7.
279	[14]	D. Eskier, G. Karakülah, A. Suner, Y. Oktay, and I. Biomedicine, "RdRp mutations are
280		associated with SARS-CoV-2 genome evolution," PeerJ, vol. 8, no. e9587, 2020, doi:
281		10.7717/peerj.9587.
282	[15]	Z. Iglói et al., "Comparison of commercial realtime reverse transcription PCR assays for the
283		detection of SARS-CoV-2," J Clin Virol., vol. Aug, p. 129:104510, Aug. 2020, doi:
284		10.1016/j.jcv.2020.104510.
285	[16]	CDC, "CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel For
286		Emergency Use Only Instructions for Use," 2020. [Online]. Available:
287		https://www.fda.gov/media/134922/download.
288	[17]	A. K. Nalla et al., "Comparative performance of SARS-CoV-2 detection assays using seven
289		different primer-probe sets and one assay kit," J. Clin. Microbiol., vol. 58, no. 6, pp. 1-6,
290		2020, doi: 10.1128/JCM.00557-20.
291	[18]	C. B. F. Vogels et al., "Analytical sensitivity and efficiency comparisons of SARS-CoV-2
292		RT-qPCR primer-probe sets," Nat. Microbiol., vol. 5, no. 10, pp. 1299-1305, 2020, doi:

293 10.1038/s41564-020-0761-6.

294 [19] S. Pfefferle, S. Reucher, D. Nörz, and M. Lütgehetmann, "Evaluation of a quantitative RT-

- 295 PCR assay for the detection of the emerging coronavirus SARS-CoV-2 using a high
- throughput system," *Eurosurveillance*, vol. 25, no. 9, Mar. 2020, doi: 10.2807/1560-
- **297** 7917.ES.2020.25.9.2000152.
- [20] G. B. Barra, T. H. S. Rita, P. G. Mesquita, R. H. Jácomo, and L. F. A. Nery, "Analytical
 sensitivity and specificity of two RT-qPCR protocols for SARS-CoV-2 detection performed in
 an automated workflow," *Genes (Basel).*, vol. 11, no. 10, pp. 1–14, Oct. 2020, doi:
- **301** 10.3390/genes11101183.
- 302 [21] J. J. LeBlanc et al., "Real-time PCR-based SARS-CoV-2 detection in Canadian laboratories,"
- 303 *J. Clin. Virol.*, vol. 128, no. January, p. 104433, Jul. 2020, doi: 10.1016/j.jcv.2020.104433.
- 304